Table 1. Baseline characteristics at time of 1L randomisation.

	ITT		Any 2L treatment		No 2L treatment
	nab-P+Gem	Gem	nab-P+Gem	Gem	nab-P+Gem	Gem
n	431	430	170a	177a	250a	226a
Age, median, years	62.0	63.0	61.0	62.0	63.0	64.0
KPS, %
90–100	58	62	68	75	52	51b
70–80	42	38	32	25	48	49b
CA19-9	n=379	n=371	n=152	n=162	n=225	n=206
U ml−1, median	2294	2759	2644	2096	1951	3733
⩾59 × ULN, %	52	53	49	46	45	50
Region, %
North America	62	63	66	63	59	60
Other	38	38	34	37	41	40
No. metastatic sites, %
1–3	86	85	88	88	85	84
>3	14	15	12	12	15	16
NLR, %	n=426	n=426
⩽5	62	65	75	73	55	58
>5	38	35	25	27	45	42

Abbreviations: 1L=first-line; 2L=second-line; CA19-9=carbohydrate antigen 19-9; Gem=gemcitabine; ITT=intention-to-treat; KPS=Karnofsky performance status; nab-P=nab-paclitaxel; NLR=neutrophil-to-lymphocyte ratio; ULN=upper limit of normal.

^aOnly patients who received 1L treatment (not the entire ITT population) were included in the Any 2L or No 2L treatment cohorts.

^bBased on 225 evaluable patients.